NBE-Therapeutics, a Switzerland-based company developing cancer therapies, has named Prof Dr Erich Schlick as independent chairman of its board of directors, it was reported on Monday.

Prof Schlick has more than 35 years' experience across the pharmaceutical and investment industry. Presently, he is the general partner and managing director at Wellington Partners. He has served as director and head of 3i Healthcare Germany and as deputy sector head of 3i Healthcare Worldwide. He has spent 15 years with BASF Pharma/Knoll AG where he was an executive board member with global responsibility for preclinical and clinical R&D.

Detlev Mennerich, partner at Boehringer Ingelheim Ventures and board member of NBE-Therapeutics, said, 'We are very pleased to welcome Prof Dr Erich Schlick to NBE-Therapeutics as chairman. His unrivalled experience and extensive network in the global life sciences industry will be invaluable to NBE-Therapeutics as it moves NBE-002, an anti-ROR1 Antibody Drug Conjugate through clinical development.'